Legend Biotech Corporation (LEGN)
Last Price$37.29.3%
Market Cap$3,309.7M
LEGN Rating
LEGN Quality rating performance
LEGN Intrinsic Value
Key Highlights:
As of Mar 11, 2025 LEGN Relative Value is $66.3, which is undervalued by 78.3%, compared to current share price of $37.2.
As of Mar 11, 2025 LEGN DCF Value is N/A, which is undervalued by N/A, compared to current share price of $37.2.
LEGN Share Price History
1W 9.4%
1M 7.4%
6M (25.2%)
YTD (37.1%)
1Y (43.0%)
3Y 3.4%
5Y 0.5%
10Y 0.5%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
LEGN Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$3,309.7M
$2,443.9M
$520.2M
($208.2M)
Shares Outstanding
89M
Employees
1,000K
Growth (CAGR)
68.9%
31.2%
12.25%
37.4%
116.3%
(70.68%)
Profitability
60.7%
(53.9%)
(66.9%)
(29.7%)
(40.0%)
60.6%
Intrinsic Value
$68.3 (83.7% undervalued)
N/A
$68.3
$237.2
(100.0%)
(51.9%)
Valuation (LTM)
Return on Capital
Financial Health
$1,212.4M
($865.8M)
4.2x
(12.6x)
31.1%
Dividends
Earnings
Aug 07, 2025
MISS by (4.9%)
BEAT by 657.1%
(121.2%)
9 Beat & 1 Miss
LEGN Stock Financials
LEGN Income Statement Metrics
Annual
Quarterly
LTM
LEGN Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($393.3M) +94.2% YoY
Capital Expenditure (CAPEX)
($22.7M) +104.4% YoY
Free Cash Flow (FCF)
($416.0M) +95.2% YoY
LEGN Income Statement Overview
Crunching data... Almost there!
LEGN Balance Sheet Overview
Annual
Quarterly
LTM
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Assets
Liabilities
Total assets
$1,848.6M
Current assets ($1,497.8M, 81.0% of total)
$1,308.7M (70.8%)
$157.1M (8.5%)
Other current assets
$32.0M (1.7%)
Non-current assets ($350.8M, 19.0% of total)
$4,362.0K (0.2%)
$189.7M (10.3%)
$4,061.0K (0.2%)
Other non-current assets
$152.7M (8.3%)
Financial position
($980.0M)
Cash & Short-term
Investments
Total Debt
LEGN Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
LEGN Earnings Surprises
Crunching data... Almost there!
LEGN Dividends
LEGN Dividend Yield
Crunching data... Almost there!
LEGN Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with LEGN
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$3,309.7M | 5.6 | $68.3 83.7% undervalued | (43.0%) | $520.2M | ($208.2M) | 123.0% | (40.0%) | 60.7% | (72.3%) | 31.1% | |
$124.8B | 5.7 | $187.5 61.6% overvalued | 17.8% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$77.0B | 6.3 | $1,048.3 46.0% undervalued | (25.4%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$34.4B | 5.8 | $123.0 78.8% overvalued | 50.8% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$30.7B | 5.2 | $91.8 61.6% overvalued | 60.1% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$24.0B | 5.9 | $191.1 94.2% undervalued | 2.2% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$14.5B | 5.4 | $71.6 120.5% undervalued | 11.2% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$13.8B | 7.7 | $542.2 78.1% undervalued | 22.0% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.4B | 6.7 | $46.9 33.5% overvalued | (18.0%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$13.3B | 5.9 | $0.6 96.9% overvalued | 330.2% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$1,846.9M | 5.5 | $2,745.6 1,111.0% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
FAQ
What is Legend Biotech Corporation (LEGN) stock rating?
As of today, Legend Biotech Corporation has a stock rating of 6 (out of 10), which is considered Good.
is Legend Biotech Corporation (LEGN) a good stock to buy?
As of today, Legend Biotech Corporation has a Good stock rating, which is 83.7% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 3.2%.